Based upon this concept, a CDK1 inhibitor was found to sensitise BRCA‐proficient cancers to PARP inhibition in human lung NSCLC xenografts.[144] Recent work with olaparib and palbociclib (a CDK4/6 inhibitor, Figure 10a) has demonstrated potent synergy in ovarian cancer cells overexpressing MYC both in vitro and in vivo. Here, PARP1 is linked to cancer.